Trial reportInternational clinical psychopharmacology2014
Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder.
Trial report in International clinical psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.Drug design, development and therapy · 2016Pooled it
- Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.International clinical psychopharmacology · 2020Trial
- The Relationship Between Depression Symptoms and Anxiety Symptoms During Acute ECT for Patients With Major Depressive Disorder.The international journal of neuropsychopharmacology · 2019Trial
- Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.The primary care companion for CNS disorders · 2016Trial
- Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.International clinical psychopharmacology · 2015Trial
- A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.Depression and anxiety · 2015Trial
- Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.Indian journal of pharmacologyTrial
- Prevalence and characteristics of anxiety in patients with unconfirmed pulmonary nodules.The clinical respiratory journal · 2023Article
- Efficacy of Deep TMS with the H1 Coil for Anxious Depression.Journal of clinical medicine · 2022Article
- Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.Neuropsychiatric disease and treatment · 2022Review
- Severity of anxiety- but not depression- is associated with oxidative stress in Major Depressive Disorder.Journal of affective disorders · 2017Article
- Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population.Neuropsychiatric disease and treatment · 2017Article
- The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.Neuropsychiatric disease and treatment · 2017Review
- The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.Expert opinion on drug discovery · 2016Review
- Emerging drugs for the treatment of anxiety.Expert opinion on emerging drugs · 2015Review
- Major depressive disorder: mechanism-based prescribing for personalized medicine.Neuropsychiatric disease and treatment · 2015Review
- Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy.Core evidence · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety symptoms are prevalent in patients with major depressive disorder. A post-hoc analysis of two phase III trials was conducted to evaluate the efficacy of vilazodone on depression-related anxiety. Using the 17-item Hamilton Depression Rating Scale (HAMD17) Anxiety/Somatization subscale, patients were classified as anxious or nonanxious. Improvements in depressive symptoms were based on least squares mean changes in HAMD17 and Montgomery-Asberg Depression Rating Scale total scores. Anxiety symptoms in the anxious subgroup were evaluated using Hamilton Anxiety Rating Scale (HAMA) total and subscale (Psychic Anxiety, Somatic Anxiety) scores, HAMD17 Anxiety/Somatization subscale and item (Psychic Anxiety, Somatic Anxiety) scores, and the Montgomery-Asberg Depression Rating Scale Inner Tension item score. Most of the pooled study population [82.0% (708/863)] was classified with anxious depression. After 8 weeks of treatment, least squares mean differences between vilazodone and placebo for changes in HAMA total and HAMD17 Anxiety/Somatization subscale scores were -1.82 (95% confidence interval -2.81 to -0.83; P<0.001) and -0.75 (95% confidence interval -1.17 to -0.32; P<0.001), respectively. Statistically significant improvements with vilazodone were also found on all other anxiety-related measures, except the HAMA Somatic Anxiety subscale. Vilazodone may be effective in treating patients with major depressive disorder who exhibit somatic and/or psychic symptoms of anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.